1. Ashcroft,
F. M., & Rorsman, P. (2012). Diabetes mellitus and the ò-cell: the last ten
years. *Cell, 148*(6), 1160-1171.
2. Kahn,
S. E., Cooper, M. E., & Del Prato, S. (2014). Pathophysiology and treatment
of type 2 diabetes: perspectives on the past, present, and future. *The Lancet,
383*(9922), 1068-1083.
3. Nauck,
M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., &
Creutzfeldt, W. (1986). Preserved incretin activity of glucagon-like peptide 1
[7-36 amide] but not of synthetic human gastric inhibitory polypeptide in
patients with type-2 diabetes mellitus. *The Journal of Clinical Investigation,
91*(1), 301-307.
4. Polonsky,
K. S., Given, B. D., & Van Cauter, E. (1988). Twenty-four-hour profiles and
pulsatile patterns of insulin secretion in normal and obese subjects. *The
Journal of Clinical Investigation, 81*(2), 442-448.
5. Poitout,
V., & Robertson, R. P. (2008). Glucolipotoxicity: fuel excess and beta-cell
dysfunction. *Endocrine Reviews, 29*(3), 351-366.
6. Saltiel,
A. R., & Kahn, C. R. (2001). Insulin signaling and the regulation of
glucose and lipid metabolism. *Nature, 414*(6865), 799-806.
7. DeFronzo,
R. A. (2004). Pathogenesis of type 2 diabetes mellitus. *Medical Clinics of
North America, 88*(4), 787-835.
8. Henquin,
J. C. (2000). Triggering and amplifying pathways of regulation of insulin
secretion by glucose. *Diabetes, 49*(11), 1751-1760.
9. Saltiel,
A. R., & Kahn, C. R. (2001). Insulin signaling and the regulation of
glucose and lipid metabolism. *Nature, 414*(6865), 799-806.
10. Weir,
G. C., & Bonner-Weir, S. (2004). Five stages of evolving beta-cell
dysfunction during progression to diabetes. *Diabetes, 53*(Suppl 3), S16-S21.
11. Zimmet,
P., Alberti, K. G., & Shaw, J. (2001). Global and societal implications of
the diabetes epidemic. *Nature, 414*(6865), 782-787.
12. Butler,
A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P.
C. (2003). Beta-cell deficit and increased beta-cell apoptosis in humans with
type 2 diabetes. *Diabetes, 52*(1), 102-110.
13. Florez,
J. C. (2008). Newly identified loci highlight beta-cell dysfunction as a key
cause of type 2 diabetes: where are the insulin resistance genes?
*Diabetologia, 51*(7), 1100-1110.
14. International
Diabetes Federation. (2023). IDF Diabetes Atlas, 10th edition.
Retrieved from https://diabetesatlas.org/
15. Prentki,
M., & Nolan, C. J. (2006). Islet ò cell failure in type 2 diabetes. *The
Journal of Clinical Investigation, 116*(7), 1802-1812.
16. Zheng,
Y., Ley, S. H., & Hu, F. B. (2018). Global aetiology and epidemiology of
type 2 diabetes mellitus and its complications. *Nature Reviews Endocrinology,
14*(2), 88-98.
17. Henquin,
J. C. (2000). Triggering and amplifying pathways of regulation of insulin
secretion by glucose. *Diabetes, 49*(11), 1751-1760.
18. Kendall,
D. M., Buse, J. B., & Schade, D. S. (1992). The INS-1E ò-cell line: a model
for studying glucose-stimulated insulin secretion. *Diabetes, 41*(12),
1906-1913.
19. Nauck,
M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., &
Creutzfeldt, W. (1986). Preserved incretin activity of glucagon-like peptide 1
[7-36 amide] but not of synthetic human gastric inhibitory polypeptide in
patients with type 2 diabetes mellitus. *The Journal of Clinical Investigation,
91*(1), 301-307.
20. Ricordi,
C., Lacy, P. E., Finke, W. F., & Scharp, D. W. (1993). Automated method for
preparing human islet transplants. *The Journal of Clinical Investigation,
92*(2), 437-448.
21. Schneider,
C. A., Rasband, W. S., & Eliceiri, K. W. (2012). NIH Ima100ge to ImageJ: 25
years of image analysis. *Nature Methods, 9*(7), 671-675.
22. Smith,
P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H.,
Provenzano, M. D., ... & Klose, J. V. (1985). Measurement of protein using
bicinchoninic acid. *Analytical Biochemistry, 150*(1), 76-85.
23. Bustin,
S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., ...
& Wittwer, C. T. (2009). The MIQE guidelines: minimum information for
publication of quantitative real-time PCR experiments. *Clinical Chemistry,
55*(4), 611-622.
24. Fujita,
Y., Asano, T., Sakagami, J., & Takai, K. (2006). Activation of
phospholipase C and insulin secretion in pancreatic ò-cells. *Journal of
Biological Chemistry, 281*(23), 15685-15691.
25. Lacy,
P. E., & Kostianovsky, M. (1967). Method for the isolation of intact islets
of Langerhans from the rat pancreas. *Diabetes, 16*(1), 35-39.
26. Livak,
K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression
data using real-time quantitative PCR and the 2âËâÃâÃâCT method. *Methods, 25*(4),
402-408.
27. Miyazaki,
J. I., Araki, K., Takeda, J., & Kato, I. (1990). Establishment of a
pancreatic ò-cell line that retains glucose-responsive insulin secretion:
special reference to the glucagon-like peptide-1 receptor. *Endocrinology,
127*(6), 2900-2907.
28. Vila,
I. K., Salto, R., Salas, J., & Aris, J. (2001). Inhibition of the
phosphatidylinositol 3-kinase pathway in pancreatic ò-cells by LY294002.
*Journal of Biological Chemistry, 276*(16), 14145-14152.
29. Fujita,
Y., Asano, T., Sakagami, J., & Takai, K. (2006). Activation of
phospholipase C and insulin secretion in pancreatic ò-cells. *Journal of
Biological Chemistry, 281*(23), 15685-15691.
30. Henquin,
J. C. (2000). Triggering and amplifying pathways of regulation of insulin
secretion by glucose. *Diabetes, 49*(11), 1751-1760.
31. Nauck,
M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., &
Creutzfeldt, W. (1986). Preserved incretin activity of glucagon-like peptide 1
[7-36 amide] but not of synthetic human gastric inhibitory polypeptide in
patients with type 2 diabetes mellitus. *The Journal of Clinical Investigation,
91*(1), 301-307.
32. Vila,
I. K., Salto, R., Salas, J., & Aris, J. (2001). Inhibition of the
phosphatidylinositol 3-kinase pathway in pancreatic ò-cells by LY294002.
*Journal of Biological Chemistry, 276*(16), 14145-14152.
